Literature DB >> 29655499

Genetic Testing in Clinical Settings.

Nora Franceschini1, Amber Frick2, Jeffrey B Kopp3.   

Abstract

Genetic testing is used for screening, diagnosis, and prognosis of diseases consistent with a genetic cause and to guide drug therapy to improve drug efficacy and avoid adverse effects (pharmacogenomics). This In Practice review aims to inform about DNA-related genetic test availability, interpretation, and recommended clinical actions based on results using evidence from clinical guidelines, when available. We discuss challenges that limit the widespread use of genetic information in the clinical care setting, including a small number of actionable genetic variants with strong evidence of clinical validity and utility, and the need for improving the health literacy of health care providers and the public, including for direct-to-consumer tests. Ethical, legal, and social issues and incidental findings also need to be addressed. Because our understanding of genetic factors associated with disease and drug response is rapidly increasing and new genetic tests are being developed that could be adopted by clinicians in the short term, we also provide extensive resources for information and education on genetic testing.
Copyright © 2018 National Kidney Foundation, Inc. All rights reserved.

Entities:  

Keywords:  APOL1; Genetic testing; ancestry; drug dosing; drug selection; gene variant; kidney disease; mutation; pharmacogenetics; pharmacogenomics; pharmacokinetics; polymorphism; review; risk allele

Mesh:

Year:  2018        PMID: 29655499      PMCID: PMC6153053          DOI: 10.1053/j.ajkd.2018.02.351

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  70 in total

1.  Finding the Rare Pathogenic Variants in a Human Genome.

Authors:  James P Evans; Bradford C Powell; Jonathan S Berg
Journal:  JAMA       Date:  2017-05-09       Impact factor: 56.272

2.  Consumer Perceptions of Interactions With Primary Care Providers After Direct-to-Consumer Personal Genomic Testing.

Authors:  Cathelijne H van der Wouden; Deanna Alexis Carere; Anke H Maitland-van der Zee; Mack T Ruffin; J Scott Roberts; Robert C Green
Journal:  Ann Intern Med       Date:  2016-03-01       Impact factor: 25.391

3.  2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis.

Authors:  Dinesh Khanna; Puja P Khanna; John D Fitzgerald; Manjit K Singh; Sangmee Bae; Tuhina Neogi; Michael H Pillinger; Joan Merill; Susan Lee; Shraddha Prakash; Marian Kaldas; Maneesh Gogia; Fernando Perez-Ruiz; Will Taylor; Frédéric Lioté; Hyon Choi; Jasvinder A Singh; Nicola Dalbeth; Sanford Kaplan; Vandana Niyyar; Danielle Jones; Steven A Yarows; Blake Roessler; Gail Kerr; Charles King; Gerald Levy; Daniel E Furst; N Lawrence Edwards; Brian Mandell; H Ralph Schumacher; Mark Robbins; Neil Wenger; Robert Terkeltaub
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-10       Impact factor: 4.794

4.  Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans.

Authors:  Hye-Ryun Kang; Young Koo Jee; Yon-Soo Kim; Chang Hwa Lee; Jae-Woo Jung; Sae Hoon Kim; Heung-Woo Park; Yoon-Seok Chang; In-Jin Jang; Sang-Heon Cho; Kyung-Up Min; Sang-Heon Kim; Kyung Wha Lee
Journal:  Pharmacogenet Genomics       Date:  2011-05       Impact factor: 2.089

5.  Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing.

Authors:  K E Caudle; A E Rettie; M Whirl-Carrillo; L H Smith; S Mintzer; M T M Lee; T E Klein; J T Callaghan
Journal:  Clin Pharmacol Ther       Date:  2014-08-06       Impact factor: 6.875

Review 6.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing.

Authors:  R S Gammal; M H Court; C E Haidar; O F Iwuchukwu; A H Gaur; M Alvarellos; C Guillemette; J L Lennox; M Whirl-Carrillo; S S Brummel; M J Ratain; T E Klein; B R Schackman; K E Caudle; D W Haas
Journal:  Clin Pharmacol Ther       Date:  2015-11-09       Impact factor: 6.875

7.  Molecular diagnosis of autosomal dominant polycystic kidney disease using next-generation sequencing.

Authors:  Adrian Y Tan; Alber Michaeel; Genyan Liu; Olivier Elemento; Jon Blumenfeld; Stephanie Donahue; Tom Parker; Daniel Levine; Hanna Rennert
Journal:  J Mol Diagn       Date:  2013-12-27       Impact factor: 5.568

8.  Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics.

Authors:  Sarah S Kalia; Kathy Adelman; Sherri J Bale; Wendy K Chung; Christine Eng; James P Evans; Gail E Herman; Sophia B Hufnagel; Teri E Klein; Bruce R Korf; Kent D McKelvey; Kelly E Ormond; C Sue Richards; Christopher N Vlangos; Michael Watson; Christa L Martin; David T Miller
Journal:  Genet Med       Date:  2016-11-17       Impact factor: 8.822

9.  HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects.

Authors:  Catherine Butkus Small; David A Margolis; Mark S Shaefer; Lisa L Ross
Journal:  BMC Infect Dis       Date:  2017-04-11       Impact factor: 3.090

10.  Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process.

Authors:  Kelly E Caudle; Teri E Klein; James M Hoffman; Daniel J Muller; Michelle Whirl-Carrillo; Li Gong; Ellen M McDonagh; Katrin Sangkuhl; Caroline F Thorn; Matthias Schwab; Jose A G Agundez; Robert R Freimuth; Vojtech Huser; Ming Ta Michael Lee; Otito F Iwuchukwu; Kristine R Crews; Stuart A Scott; Mia Wadelius; Jesse J Swen; Rachel F Tyndale; C Michael Stein; Dan Roden; Mary V Relling; Marc S Williams; Samuel G Johnson
Journal:  Curr Drug Metab       Date:  2014-02       Impact factor: 3.731

View more
  10 in total

Review 1.  APOL1 Genetic Testing in Living Kidney Transplant Donors.

Authors:  Sumit Mohan; Ana S Iltis; Deirdre Sawinski; James M DuBois
Journal:  Am J Kidney Dis       Date:  2019-04-11       Impact factor: 8.860

2.  Autosomal dominant osteopetrosis type II resulting from a de novo mutation in the CLCN7 gene: A case report.

Authors:  Xiu-Li Song; Li-Yuan Peng; Dao-Wen Wang; Hong Wang
Journal:  World J Clin Cases       Date:  2022-07-16       Impact factor: 1.534

Review 3.  Human Leukocyte Antigen (HLA) System: Genetics and Association with Bacterial and Viral Infections.

Authors:  Sadeep Medhasi; Narisara Chantratita
Journal:  J Immunol Res       Date:  2022-05-26       Impact factor: 4.493

4.  Analytical validity of a genotyping assay for use with personalized antihypertensive and chronic kidney disease therapy.

Authors:  Kimberly S Collins; Victoria M Pratt; Wesley M Stansberry; Elizabeth B Medeiros; Karthik Kannegolla; Marelize Swart; Todd C Skaar; Arlene B Chapman; Brian S Decker; Ranjani N Moorthi; Michael T Eadon
Journal:  Pharmacogenet Genomics       Date:  2019-01       Impact factor: 2.089

Review 5.  Gene variants and treatment outcomes in antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Arno C Hessels; Jan Stephan F Sanders; Abraham Rutgers; Coen A Stegeman
Journal:  Pharmacogenomics J       Date:  2020-07-18       Impact factor: 3.550

Review 6.  Ethical, Legal, and Social Issues Related to the Inclusion of Individuals With Intellectual Disabilities in Electronic Health Record Research: Scoping Review.

Authors:  Melissa Raspa; Rebecca Moultrie; Laura Wagner; Anne Edwards; Sara Andrews; Mary Katherine Frisch; Lauren Turner-Brown; Anne Wheeler
Journal:  J Med Internet Res       Date:  2020-05-21       Impact factor: 5.428

Review 7.  Genetic testing-whether to allow complete freedom? Direct to consumer tests versus genetic tests for medical purposes.

Authors:  Madej Malgorzata; Sąsiadek Maria; Witt Michał
Journal:  J Appl Genet       Date:  2021-11-26       Impact factor: 3.240

8.  Effects of Testing and Disclosing Ancestry-Specific Genetic Risk for Kidney Failure on Patients and Health Care Professionals: A Randomized Clinical Trial.

Authors:  Girish N Nadkarni; Kezhen Fei; Michelle A Ramos; Diane Hauser; Emilia Bagiella; Stephen B Ellis; Saskia Sanderson; Stuart A Scott; Tatiana Sabin; Ebony Madden; Richard Cooper; Martin Pollak; Neil Calman; Erwin P Bottinger; Carol R Horowitz
Journal:  JAMA Netw Open       Date:  2022-03-01

9.  Ethical Implications of Alzheimer's Disease Prediction in Asymptomatic Individuals through Artificial Intelligence.

Authors:  Frank Ursin; Cristian Timmermann; Florian Steger
Journal:  Diagnostics (Basel)       Date:  2021-03-04

10.  Physicians' Attitudes and Ethical Obligations to Pharmacogenetic Testing.

Authors:  Suhaib Muflih; Belal A Al-Husein; Reema Karasneh; Karem H Alzoubi
Journal:  J Multidiscip Healthc       Date:  2020-03-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.